Resilience Raises $625M in Series D Financing


National Resilience, Inc., a San Diego, CA-based technology-focused biomanufacturing company dedicated to broadening access to complex medicines, raised $625m in Series D financing.

The latest up-round financing – in addition to a previously unannounced $600m Series C financing completed in August 2021 – was led by new and existing investors, including venture capital funds, public mutual funds, pension funds, biopharma companies, sovereign wealth funds and private family offices, among others. In total, Resilience has secured more than $2 billion in equity financing since its founding in 2020.

The company intends to use the funds to continue to invest in building its infrastructure network through strategic collaborations, acquisitions, organic growth and international expansion, and by developing innovative biomanufacturing technologies to ensure the medicines of today and tomorrow can be made, at scale. It is also investing in advanced R&D, including stable cell lines for viral vector production, distributed manufacturing for autologous cell therapy and cell-free and continuous manufacturing for biologics.

Founded in 2020 and led by Rahul Singhvi, Sc.D., Chief Executive Officer, Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines.

Resilience, which focuses on five therapeutic modalities – biologics, vaccines, nucleic acids and cell and gene therapies – currently has 10 facilities across North America, with more than 1 million square feet of manufacturing space and more than 1,600 employees.

The company recently acquired SwiftScale Biologics, a company developing cell-free protein synthesis, established a multi-product development and manufacturing collaboration with Takeda’s Plasma-Derived Therapies Business Unit, secured a contract with the U.S. Department of Defense for manufacturing a monoclonal antibody as a medical countermeasure to botulinum neurotoxins, and signed a strategic manufacturing services agreement with Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases.

They also acquired bluebird bio’s Research Triangle manufacturing facility in North Carolina, added capacity and capabilities including drug substance and drug product manufacturing expansions coming online in 2022 across sites in Alachua, FL, Boston and Toronto, to support biologics and vaccines

Resilience also formed a strategic collaboration with Be Biopharma to manufacture engineered B Cells to create a new class of autologous and allogeneic cellular medicines.